Karen Piper Hanley is Professor of Molecular Medicine and Head of Division in the Division of Diabetes, Endocrinology & Gastroenterology at the University of Manchester. She serves as the fibrosis lead in the Wellcome Trust Centre for Cell-Matrix Research and previously served as Director of Core Research Technologies (2019-2022). She is also an editorial board member for Scientific Reports. Her research focuses on fibrosis (scarring) mechanisms across multiple organs, particularly liver, kidney, and lung fibrosis. Her lab investigates the cellular and molecular basis of fibrotic disease, with emphasis on how pathological scar components are produced and how they signal to surrounding cells. Key areas include the role of SOX9 transcription factor, integrin beta-1 signaling, Group 1 PAKs, and YAP1 in fibrosis progression. Her recent publications reveal trends toward increased clinical translation of fibrosis research, with studies on health inequalities in liver cancer care, post-COVID diabetes incidence, and innovative approaches to liver disease detection. Her work increasingly integrates spatial transcriptomics and advanced omics technologies to understand cellular transitions in liver disease. Career-track postdoctoral fellowship from the University of Southampton (2006) As senior postgraduate tutor, she has mentored numerous PhD students who have presented at key conferences and authored high-quality manuscripts. All her PhD students have submitted and been awarded their degrees within 4 years. She has successfully guided previous Academic Clinical Fellows to win MRC clinical training fellowships. Her teaching extends to undergraduate Personal & Professional Development and supervision of MRes and BSc students, many of whom have achieved first-class degrees and prestigious awards. Her lab maintains active collaborations with Professor Neil Hanley's group on human development, stem cells, and regenerative medicine, bridging developmental biology with fibrosis research to understand why regeneration is impaired in chronic diseases.
Rotem Karni, PhD, is an Associate Professor of Genetics at the Perelman School of Medicine, University of Pennsylvania, Philadelphia. He leads a research lab focused on understanding how alternative RNA splicing contributes to cancer and genetic diseases, with a strong emphasis on translating these findings into RNA-based therapies. Karni's lab develops decoy oligonucleotides, small molecules, and splice-switching technologies to modulate splicing factors and enhance immunotherapy. Education BSc in Biological Chemistry from The Hebrew University of Jerusalem (1997) PhD in Biological Chemistry from The Hebrew University of Jerusalem, Israel (2002) Postdoctoral Fellowship at Cold Spring Harbor Laboratory, NY (2002-2007) Karni's research explores the deregulation of alternative splicing in oncogenesis, particularly how splicing factors like RBFOX2 and S6K1 influence metastasis, DNA repair, and immune checkpoint modulation. His team investigates m6A RNA modifications for stabilizing mutant genes, with applications in Duchenne Muscular Dystrophy and pancreatic cancer. The lab's work is commercialized through biotech companies: SKIP Therapeutics, Andlit Therapeutics, and RNAble. Selected Research Trends RNA mis-splicing and neoantigen generation (2025) Splicing factor inhibition for tumor suppression (2023) Metastatic splicing signatures in pancreatic cancer (2023) Immune checkpoint splicing in cancer immunotherapy (2021) m6A modulation for mRNA stabilization (2023) Advising & Collaborations Karni has mentored numerous PhD and postdoctoral researchers, many of whom now hold leadership roles in academia, biotech, and medical institutions globally. His lab collaborates extensively on projects involving RNA innovation, including partnerships with the Institute for RNA Innovation. Contact Department of Genetics & Institute for RNA Innovation, One uCity Square, Room 4018, Philadelphia, PA 19104 Phone: 215-898-5072 Email: Rotem.Karni@Upenn.edu
University of North Carolina at Chapel HillUnited States
Dr. Hongtu Zhu is the Kenan Distinguished Professor of Biostatistics, Statistics, Radiology, Computer Science, and Genetics at the University of North Carolina at Chapel Hill (UNC). He holds affiliations with the Gillings School of Global Public Health and leads the Biostatistics and Imaging Genomics Analysis Lab. His expertise spans statistical learning, medical imaging, AI, and big data integration, with a focus on precision medicine and biomedicine. Dr. Zhu earned his PhD in Statistics from The Chinese University of Hong Kong (2000) and has held prior roles including DiDi Fellow/Chief Scientist (2018-2020) and Bao-Shan Jing Endowed Professor at MD Anderson Cancer Center (2016-2018). He has published over 345 peer-reviewed articles in top-tier journals like Nature, Science, and JASA, and actively contributes to editorial roles including Coordinating Editor of JASA. His research interests include neuroimaging analysis, knowledge graphs, and AI applications in healthcare. Notable awards include the COPSS Snedecor Award (2025), IEEE Fellowship (2025), and IMS Medallion (2027). He has mentored over 80 PhD students/postdoctoral fellows and serves on NIH grant review panels and professional organizations like the ASA's Section on Statistics in Imaging. Key Contributions: Imaging genomics, brain connectivity studies, ridesharing market optimization, medical AI frameworks Lab Innovations: Brain Imaging Genetics Knowledge Portal, Biomedical Knowledge Graph Interface Teaching: Advanced biostatistics courses (Generalized Linear Models, Deep Learning in Biomedicine) Recent work explores causal inference in healthcare, X chromosome's role in neurobiology, and AI ethics in medical vision-language models. His interdisciplinary projects bridge statistics, computer science, and clinical practice to address complex biomedical challenges.
Michael Kjær is a Clinical Professor at the Department of Clinical Medicine, University of Copenhagen, Faculty of Health and Medical Sciences. He specializes in Internal Medicine: Rheumatology and leads research groups focused on exercise physiology, sports injuries, and aging. His work addresses the impact of physical activity on the human organism, with particular emphasis on tissue damage and repair mechanisms. Dr. Kjær's primary research interests center around sports medicine, physiology, and exercise science. His work investigates tendon pathology, muscle physiology, sports injuries, and the effects of exercise on aging populations. He has made significant contributions to understanding sports-related injuries, particularly tendon overuse conditions, and the physiological responses to physical activity across different age groups. His recent publications (2025) demonstrate a strong focus on tendon research, sports injury treatment dilemmas, effects of anabolic steroid abuse, muscle physiology, and bone health in athletes and older adults. The research spans from basic science investigations of cellular mechanisms to clinical studies addressing practical sports medicine challenges. His work shows particular strength in connecting molecular and tissue-level changes with clinical outcomes in sports medicine. With 415 research outputs including 369 journal articles, 15 book chapters, and 15 reviews, Dr. Kjær maintains an active research program with substantial impact. His work has been referenced in Wikipedia pages, cited by Bluesky users, and picked up by news outlets, demonstrating its relevance to both academic and public discourse. Dr. Kjær leads multiple research groups within the Center for Healthy Aging Damage and Repair at the Department of Clinical Medicine. His laboratory work focuses on tissue response to injury and exercise, particularly examining tendon and muscle physiology using both in vivo and in vitro approaches. His research bridges basic science with clinical applications in sports medicine and rehabilitation.
Swiss Federal Institute of Technology in LausanneSwitzerland
Kristina Schoonjans is an Associate Professor at EPFL’s School of Life Sciences, where she leads the Laboratory of Metabolic Signaling (UPSCHOONJANS). Her research focuses on the molecular mechanisms of bile acid signaling, nutrient sensing, and intermediary metabolism, particularly in the context of metabolic disorders such as obesity, fatty liver disease, and cancer. She investigates how the liver-gut-brain axis integrates metabolic signals through nuclear receptors and mitochondrial dynamics. Her research interests include: Bile acid signaling and its role as a hormonal regulator Nutrient and metabolite sensing in energy homeostasis Intermediary metabolism and metabolic disorders Role of nuclear receptors (e.g., TGR5, LRH-1) in liver, gut, and adipose tissue Mitochondrial dynamics and fission in metabolic regulation Organoid models for studying liver and intestinal metabolism Systems genetics using BXD mouse populations The most recent articles highlight a strong focus on bile acid signaling, particularly through TGR5 and LRH-1, in regulating metabolic health. Themes include the conversion of white fat to beige fat (beiging), hepatic tumorigenesis, mitochondrial fission, and the use of organoid and genetically engineered mouse models. There is a consistent emphasis on translational applications for obesity, fatty liver disease, and cancer. Scientific honors include: Windaus Prize from the Dr. Falk Foundation (2010, shared with Johan Auwerx) for the discovery of the signaling/endocrine function of bile acids Prof. Schoonjans actively supervises PhD students and has advised numerous doctoral candidates who have since completed their theses. Her lab is supported by multiple grants from Swiss and international funding agencies, including the Swiss National Science Foundation, EPFL, CONACYT, and the Foundation for Health and Education. She teaches in several doctoral programs at EPFL, including Life Sciences Engineering, and contributes to education through the SSV and EDBB/EDCB/EDMS-ENS programs. The Schoonjans Lab brings together scientists, doctoral assistants, and technicians working on projects related to metabolic signaling. The team uses advanced techniques such as genetically modified mouse models, organoid cultures, and multi-omics (metabolomics, proteomics, transcriptomics) to study the liver-gut and brain-liver axes. The lab has a strong track record of high-impact publications and collaborations with institutions worldwide.
University of California, San FranciscoUnited States
Iona Cheng is a Professor in the Department of Epidemiology and Biostatistics at the University of California, San Francisco (UCSF), where she conducts groundbreaking research in cancer epidemiology. She serves as co-Investigator of the SEER Greater Bay Area Cancer Registry and is Principal Investigator of multiple NIH- and foundation-funded projects examining genetics, lifestyle factors, and neighborhood characteristics in relation to cancer risk. Dr. Cheng has developed an extensive research program focused on racial/ethnic differences in cancer risk and leads population-based cancer surveillance studies that document variations in cancer incidence and mortality patterns across diverse racial and ethnic groups. University of California, Davis, BS, 1990–1994, Physiology Yale University, MPH, 1999–2001, Chronic Disease Epidemiology University of Southern California, PhD, 2001–2005, Epidemiology University of California, San Francisco, Postdoc, 2006–2008, Genetic and Molecular Epidemiology Dr. Cheng's research spans multiple disciplines within cancer epidemiology, with particular emphasis on understanding how environmental exposures, genetic factors, and social determinants interact to influence cancer risk and outcomes across different racial and ethnic populations. Her work frequently examines the impact of air pollution, endocrine-disrupting chemicals, and neighborhood characteristics on cancer development and survival. She has made significant contributions to understanding cancer disparities among Asian American, Native Hawaiian, and Pacific Islander populations, bringing attention to the unique cancer risks and outcomes within these understudied groups. Her research often leverages the Multiethnic Cohort Study, one of the largest prospective studies of cancer incidence and mortality across diverse racial/ethnic populations. Analysis of Dr. Cheng's recent publications reveals a consistent focus on environmental and social determinants of cancer risk across multiple organ sites. Her work demonstrates a sophisticated integration of epidemiological methods with environmental exposure assessment, genetic analysis, and health disparities research. Many of her studies examine the intersection of environmental exposures and racial/ethnic disparities in cancer outcomes, particularly regarding breast cancer, lung cancer, and other malignancies. She has published extensively on the impact of air pollution on cancer risk and survival, as well as the effects of endocrine-disrupting chemicals like bisphenol A, parabens, and phthalates. American Association for Cancer Research Scholar-in-Training Award (2007) National Institutes of Health Loan Repayment Award (2007) National Institutes of Health Loan Repayment Renewal Award (2009) American Association for Cancer Research Faculty Scholar Award (2011) National Institutes of Health Loan Repayment Renewal Award (2011) National Institutes of Health Loan Repayment Renewal Award (2013) American Journal of Epidemiology/Society of Epidemiology Research Top 10 manuscripts (2014) Cancer Prevention Institute of California Mentoring Award (2015) American Society of Human Genetics Top poster As Principal Investigator of multiple NIH-funded projects, Dr. Cheng oversees substantial research grants focused on cancer epidemiology and health disparities. Her work often involves large interdisciplinary collaborations with researchers across multiple institutions, including the Multiethnic Cohort Study which follows over 200,000 participants from diverse racial/ethnic backgrounds. She has demonstrated leadership in mentoring junior researchers, particularly those from underrepresented backgrounds in science, as evidenced by her Cancer Prevention Institute of California Mentoring Award. Her research program integrates data from cancer registries, electronic health records, and geospatial information to provide comprehensive insights into cancer patterns and risk factors. Dr. Cheng's research is closely connected to the UCSF Helen Diller Family Comprehensive Cancer Center and leverages collaborations with Lawrence Berkeley National Laboratory, which provides advanced technological resources for cancer research. Her work benefits from access to extensive cohort data, sophisticated exposure assessment methods, and interdisciplinary expertise in genetics, environmental science, and computational biology available through these institutional partnerships. She frequently collaborates with researchers studying the genetic and environmental determinants of cancer across multiple organ systems, contributing to a more comprehensive understanding of cancer etiology and prevention strategies.
Gabriela Minigo serves as an Honorary Fellow in Global and Tropical Health and Associate Dean - Learning and Teaching within the Faculty of Health. Her academic profile demonstrates active engagement in malaria immunology research with a recent expansion into circadian rhythm and metabolic health investigations. Dr. Minigo completed her PhD at the University of Melbourne (awarded March 31, 2007) and earned a Master of Clinical Epidemiology from the University of Newcastle (awarded December 8, 2017). Her educational background provides a strong foundation in both basic science and clinical epidemiology. Her primary research focuses on immunological responses to malaria, with particular expertise in T follicular helper cells, dendritic cell function, and regulatory T cells in Plasmodium falciparum and Plasmodium vivax infections. Analysis of her research fingerprint reveals significant contributions to Plasmodium falciparum Immunology and Microbiology (100%), Dendritic Cell Immunology and Microbiology (45%), Regulatory T Cell Immunology and Microbiology (38%), and other related fields. In recent years, she has expanded her research to investigate the relationship between photoperiod, circadian rhythm, and metabolic health, as evidenced by her 2024 publications on these topics. Dr. Minigo's scholarly output shows an evolving research trajectory from fundamental malaria immunology toward interdisciplinary investigations connecting circadian biology with metabolic health. Her recent publications (2022-2024) demonstrate continued strong contributions to malaria immunology while incorporating new dimensions related to light exposure, sleep patterns, and glucose control. She has secured research funding for multiple projects including 'Rainmaker start up- Does exposure to artificial light alter circadian rhythm and glucose control in Australian adults? A pilot study' (2023-2026) where she serves as Co-Investigator, and 'Effect of Extended Photoperiod Exposure on Circadian Rhythm and Glucose Control' (2024-present) where she is Principal Investigator. Previously, she contributed as Chief Investigator C to 'Manipulating T follicular helper cells to improve human malaria vaccines' (2020-2023). As Associate Dean for Learning and Teaching, Dr. Minigo holds significant educational leadership responsibilities within the Faculty of Health. She is registered to supervise postgraduate research, indicating her active role in mentoring graduate students in immunology and tropical medicine research.
Dr. Sharon K. Sagiv is an Adjunct Assistant Professor of Epidemiology at UC Berkeley's School of Public Health and an investigator at the Center for Environmental Research and Children’s Health. Her research focuses on prenatal and early-life environmental toxin exposures, particularly persistent organic pollutants, heavy metals, pesticides, and consumer chemicals, and their impacts on child neurodevelopment. She has extensively studied associations between environmental toxicants and neurodevelopmental disorders like ADHD and autism, alongside innovative work using functional neuroimaging to assess neural activity in exposed populations. Dr. Sagiv holds a PhD in Epidemiology from UNC Chapel Hill (2004), an MPH from Boston University (1998), and a BA in Biology from Franklin and Marshall College (1993). She has contributed to major cohorts such as CHAMACOS and Project Viva, examining long-term effects of pollutants like PFAS, organophosphates, and PBDEs. Her work bridges epidemiology, toxicology, and neuroimaging to advance understanding of environmental health risks. Research interests emphasize translational environmental health science, with a focus on pesticide mixtures, air pollution, and endocrine disruptors. Key themes include exposure assessment frameworks, functional neuroimaging outcomes, and developmental origins of health disparities. She teaches grant-writing seminars and collaborates globally on pesticide neurotoxicity studies in farmworker populations. Recent publications highlight links between prenatal PFAS exposure and metabolic outcomes, pesticide exposure and brain connectivity, and traffic pollution’s role in neurocognitive decline. Her research portfolio includes systematic reviews on air pollution health impacts and methodological innovations for assessing chemical mixtures in pregnancy. Dr. Sagiv’s work has policy implications for environmental regulations and public health interventions targeting vulnerable populations.
Katie L. Kaput is a Clinical Associate Professor in the Department of Internal Medicine at the University of Utah School of Medicine. She provides high-quality, personalized endocrine care with a focus on preventative health and chronic illness management at the Sugar House Health Center in Salt Lake City, Utah. Education: Bachelor's in Biology from the University of Georgia, Medical Degree from Michigan State College of Osteopathic Medicine, Residency at National Jewish Health/Saint Joseph Hospital, and Endocrinology Fellowship at the University of Utah. Research & Clinical Interests: Span endocrinology and internal medicine, with expertise in Adrenal and Parathyroid Disorders Osteoporosis & Metabolic Bone Disease Thyroid and Pituitary Disorders Transgender Health Cystic Fibrosis Endocrinology Clinical Excellence: Patient testimonials highlight her exceptional bedside manner, expertise, and patient-centered approach. She works alongside Heather and Kaj, noted for their professionalism and care.
Angelica Lindén Hirschberg is a Professor of Obstetrics and Gynecology (specializing in reproductive medicine) at Karolinska Institutet and a Senior Consultant in gynecological endocrinology at Karolinska University Hospital. She holds dual roles in academic leadership and clinical practice, focusing on disorders of reproductive function, endocrine-metabolic dysfunction, and hormonal conditions in women. Her affiliations include the Department of Women’s and Children’s Health, Reproductive Endocrinology and Metabolism Research Group, and the Division for Neonatology, Obstetrics, Gynaecology, and Reproductive Health. Education and Career: MD (Karolinska Institutet, 1984) PhD (Karolinska Institutet, 1989) Professor in Obstetrics and Gynecology (2007) Board member of international societies (ISGE, EMAS) Research Focus: Her translational research spans PCOS, obesity-related reproductive dysfunction, premature ovarian insufficiency, and disorders of sex development. Projects include hormonal impacts on athletic performance, immune therapy for ovarian dysfunction, and endometrial cell biology. Collaborations involve national/international networks and clinical trials (e.g., PROBES trial). Publications: Recent work emphasizes PCOS pathophysiology, menopausal health, and hormonal interventions in athletes. Key trends include single-cell profiling of endometrium, immunomodulatory therapies for POI, and non-hormonal treatments for vasomotor symptoms. Awards: King’s Seraphim Medal (2018) 2016 Grand Prize in Sport Science Appointed Royal Gynecologist (2009) Teaching and Mentorship: Coordinates courses on reproductive endocrinology, supervises PhD students (e.g., Esin Ylmaz), and chairs the PhD Study Director at her department. Authored over 25 book chapters on women’s health and sports medicine. Grants and Labs: Secured Swedish Research Council funding for POI trials. Her lab integrates experimental (Bioclinicum) and clinical (Women’s Health Research Unit) research.
Lloyd D. Petty, DO, MPH, is a Clinical Assistant Professor in the Department of Internal Medicine at the University of Utah School of Medicine. He specializes in Endocrinology, Diabetes & Metabolism, providing clinical care while contributing to academic research. Education: D.O. and M.P.H. from Nova Southeastern University College of Osteopathic Medicine; B.S. in Physiology from University of Arizona Training: Chief Residency at University of New Mexico School of Medicine; Fellowship in Endocrinology at University of Utah School of Medicine His research focuses on endocrine disorders, particularly diabetes, osteoporosis, and thyroid diseases. Recent publications explore hormonal-gastrointestinal interactions, bone health in oncology patients, and minimally invasive endocrine procedures. Key publications span bone metabolism in chronic lymphocytic leukemia (2024), adrenal gland ablation techniques (2022), and endocrine-gastrointestinal case studies (2017-2023). The work demonstrates expertise in clinical endocrinology applications.
Martin Jastroch is a Professor at Stockholm University's Department of Molecular Biosciences, The Wenner-Gren Institute. His research focuses on the physiology and molecular mechanisms of energy metabolism from organism to molecule level. His primary research interests include: Energy metabolism physiology and molecular mechanisms Obesity and metabolic aspects Adipose tissue biology Mitochondrial mechanisms Thermogenesis and brown fat function Metabolic regulation in health and disease Professor Jastroch's research spans multiple disciplines, connecting molecular mechanisms with whole-organism physiology. His work on mitochondrial bioenergetics and thermogenesis has contributed significantly to understanding how energy metabolism is regulated across different biological scales. Recent publications show a growing interest in the evolutionary aspects of thermogenesis and the role of brown adipose tissue in metabolic diseases, with particular focus on UCP1 function, mitochondrial adaptations, and metabolic reprogramming in disease states. His scientific contributions include important findings on: UCP1 (Uncoupling Protein 1) function and regulation Mitochondrial bioenergetics in different tissue types Evolutionary aspects of mammalian thermogenesis Metabolic regulation in obesity and related disorders Links between mitochondrial dysfunction and neurodegenerative diseases Professor Jastroch leads 'Group Jastroch' at Stockholm University, where his team investigates the complex interplay between cellular energy metabolism and whole-body physiology, with implications for understanding and treating metabolic disorders.
University Medical Center Hamburg-EppendorfGermany
Prof. Dr. med. Franz Lennard Ricklefs is a Senior Physician and Head of the Working Group at the Department of Neurosurgery, University of Hamburg Faculty of Medicine. He is a Medical Specialist in Neurosurgery with cross-disciplinary expertise in neuro-oncology, molecular pathology, and extracellular vesicle research. Affiliations: University Medical Center Hamburg-Eppendorf (UKE), European Liquid Biopsy Society (ELBS), International Consortium on Meningiomas (ICOM) Research Interests: His work focuses on neurosurgical oncology, particularly glioblastoma and meningioma pathobiology. He investigates DNA methylation patterns, extracellular vesicle biomarkers, and liquid biopsy implementation in clinical neuro-oncology. Additional interests include surgical outcomes for epilepsy and aneurysm management. Article Trends: Over the last decade, Dr. Ricklefs has published extensively on: Extracellular vesicle applications as liquid biopsy markers DNA methylation subclasses for glioblastoma and meningioma Multicenter surgical outcome benchmarking Immune evasion mechanisms in neuro-oncology Technological innovations in neurosurgical visualization Molecular characterization of rare CNS tumors Professional Contributions: He co-authored the MISEV2023 guidelines for extracellular vesicle studies and participates in international consensus reviews for meningioma classification. His collaborations span institutions across Europe and North America.
Antti Poso is a Professor of Drug Design at the University of Eastern Finland (Kuopio), affiliated with the School of Pharmacy under the Faculty of Health Sciences. His research focuses on computer-aided molecular design, particularly targeting anti-cancer drugs and anti-microbials. Key projects include the EDCMET project (2019–2024) and the GeneCellNano Flagship (2020–2028). He leads the Molecular Modeling and Drug Design Research Group, specializing in QSAR analysis, kinase inhibition profiling, and systems-level drug response modeling. Recent work includes studies on SARS-CoV-2 inhibitors, endocrine disruptors, and bacterial pathogenesis. His findings bridge chemical structure with biological outcomes, leveraging computational tools like CCA and molecular dynamics simulations. Collaborations span medicinal chemistry, pharmacology, and systems biology, contributing to both academic and applied drug discovery efforts. Education: Not explicitly stated in texts; assumed to hold advanced degrees in pharmacy or chemistry. Research Themes: Drug design, molecular modeling, QSAR, computational biology, and anti-infective agents. Key Contributions: Over 150+ publications, including influential works on chemoinformatics-driven drug response analysis and structure-based inhibitor design. Publications highlight advancements in kinase inhibitors, anti-microbial strategies, and viral hijacking mechanisms. His work emphasizes translating computational insights into therapeutic solutions for cancer, infectious diseases, and metabolic disorders.
Carmen Soto-Rivera is an Instructor of Pediatrics at Harvard Medical School and holds dual directorships as Director of the Neuroendocrinology and Cancer Survivorship Program (NECS) and Director of the Growth Program. She is affiliated with Boston Children’s Hospital across three locations in Boston, Norwood, and Weymouth, Massachusetts. Her clinical expertise spans Growth Problems, Hypopituitarism, and Type 1 Diabetes, with programmatic leadership in Endocrinology and Neuroendocrinology. Dr. Soto-Rivera completed her undergraduate studies at the University of Puerto Rico (2003), medical degree from University of Puerto Rico School of Medicine (2007), and residency at University Pediatric Hospital, Puerto Rico, culminating as Chief Resident in 2011. She specialized in Pediatric Endocrinology via a fellowship at Boston Children’s Hospital (2014). She is dually certified by the American Board of Pediatrics in both General Pediatrics and Endocrinology. Her research focuses on neonatal endocrine disorders, exemplified by a 2015 publication in Endocrine exploring thyroid-stimulating hormone (TSH) dynamics in preterm infants. While no formal grants or awards are listed, her clinical and programmatic roles reflect significant contributions to pediatric endocrine care. She leads multidisciplinary teams across three clinical sites, though specific lab or team affiliations are not detailed. Fluent in both English and Spanish, she provides culturally competent care to diverse populations.
